Inhaled nitric oxide in the neonate

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Cardiovascular Physiology

Background:

• Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used in neonatal respiratory failure.
• Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in term infants.
• Preterm infants often experience respiratory challenges with pulmonary vascular resistance components.

Purpose of the Study:

• To evaluate the efficacy of inhaled nitric oxide (iNO) in term and preterm infants with respiratory failure.
• To assess iNO's impact on oxygenation and the need for extracorporeal membrane oxygenation (ECMO).
• To determine iNO's effectiveness in specific neonatal conditions like PPHN and congenital diaphragmatic hernia (CDH).

Main Methods:

• Review of clinical data on iNO administration in term and preterm infants.
• Analysis of oxygenation indices and ECMO requirements in infants treated with iNO.
• Comparison of iNO treatment outcomes across different neonatal respiratory conditions.

Main Results:

• Term infants with PPHN showed improved oxygenation and reduced ECMO need with iNO.
• Infants with congenital diaphragmatic hernia (CDH) demonstrated minimal clinical benefit from iNO.
• Preterm infants exhibited limited benefits from iNO, both early and late in their disease course.

Conclusions:

• iNO is effective for term infants with PPHN, improving oxygenation and reducing ECMO use.
• iNO provides little clinical benefit for infants with CDH.
• The utility of iNO in preterm infants for respiratory failure or chronic lung disease prevention is limited.